talquetamab
Selected indexed studies
- Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. (N Engl J Med, 2022) [PMID:36507686]
- Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions. (Eur J Haematol, 2025) [PMID:39604778]
- Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. (N Engl J Med, 2025) [PMID:39778168]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. (2025) pubmed
- Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. (2022) pubmed
- Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions. (2025) pubmed
- Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. (2025) pubmed
- Talquetamab: First Approval. (2023) pubmed
- Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. (2025) pubmed
- Talquetamab. (2006) pubmed
- Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. (2021) pubmed
- Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab. (2024) pubmed
- Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. (2025) pubmed